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Abstract
Tobacco use is a major contributor to premature morbidity and mortality. The measurement of nicotine and its metabolites
in urine is a valuable tool for evaluating nicotine exposure and for nicotine metabolic profiling—i.e., metabolite ratios. In
addition, the minor tobacco alkaloids—anabasine and anatabine—can be useful for monitoring compliance in smoking
cessation programs that use nicotine replacement therapy. Because of an increasing demand for the measurement of
urinary nicotine metabolites, we developed a rapid, low-cost method that uses isotope dilution liquid chromatography-
tandem mass spectrometry (LC-MS/MS) for simultaneously quantifying nicotine, six nicotine metabolites, and two minor
tobacco alkaloids in smokers’ urine. This method enzymatically hydrolyzes conjugated nicotine (primarily glucuronides) and
its metabolites. We then use acetone pretreatment to precipitate matrix components (endogenous proteins, salts,
phospholipids, and exogenous enzyme) that may interfere with LC-MS/MS analysis. Subsequently, analytes (nicotine,
cotinine, hydroxycotinine, norcotinine, nornicotine, cotinine N-oxide, nicotine 19-N-oxide, anatabine, and anabasine) are
chromatographically resolved within a cycle time of 13.5 minutes. The optimized assay produces linear responses across the
analyte concentrations typically found in urine collected from daily smokers. Because matrix ion suppression may influence
accuracy, we include a discussion of conventions employed in this procedure to minimize matrix interferences. Simplicity,
low cost, low maintenance combined with high mean metabolite recovery (76–99%), specificity, accuracy (0–10% bias) and
reproducibility (2–9% C.V.) make this method ideal for large high through-put studies.
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Introduction
Monitoring tobacco exposure by the use of urinary nicotine
metabolite analysis has become an informative tool for evaluating
the effectiveness of regulations intended to limit public exposure
and tobacco distribution to minors [1]. Further, understanding the
various metabolic processes involved in nicotine uptake and
clearance may aid in optimizing and customizing cessation
programs to improve their success rates [2,3]. Urinary nicotine
metabolite measurement may also be helpful for estimating the
effectiveness of nicotine delivery systems (smokeless tobacco
products) and nicotine replacement therapies (patch, gum, and
inhalers). Urine nicotine metabolite profiles of tobacco users have
been essential for the identification of variations in the metabolic
processing of nicotine by selected population groups [4–10]. The
minor tobacco alkaloids—anatabine and anabasine—are included
in this method because they are detectable in tobacco smokers’
urine and are not metabolites of nicotine. Because the use of
nicotine gum, inhalers, or other nicotine delivery devices should
not provide detectable amounts of these two alkaloids, the
detection of anatabine and anabasine in the urine of participants
in nicotine replacement therapy tobacco cessation programs can
provide an indication of non-compliance [11,12].
Following nicotine uptake in the body, nicotine is metabolized
mainly via the P450 enzyme system to six primary metabolites:-
cotinine, hydroxycotinine, norcotinine, nornicotine, cotinine
oxide, and nicotine oxide (Figure 1) [9]. In this paper we
describe a LC-MS/MS method for determining concentrations of
nicotine, these six nicotine metabolites, and two minor tobacco
alkaloids—anabasine and anatabine—in urine. Nicotine and two
metabolites—cotinine and hydroxycotinine—form substantial
levels of conjugates (primarily glucuronides) that are excreted in
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the urine. We report these metabolites as ‘‘free’’ (non-conjugated
forms) and ‘‘total’’ (sum of conjugated and non-conjugated forms).
Individual measurement of the ‘‘free’’ and the ‘‘total’’ may provide
useful metabolic rate information, such as the rate of individual or
ethnic variations in glucuronidation [4]. Glucuronidation of toxins
tends to increase their water solubility and accelerate their removal
from the body through urinary excretion. For analysis of ‘‘total’’
analytes, we used b-glucuronidase to enzymatically remove the
conjugated moiety. For measurement of ‘‘free’’ analytes, no
enzymatic hydrolysis was performed prior to the acetone
precipitation step and the subsequent LC-MS/MS analysis.
Several LC-MS/MS methods are available for determination of
nicotine metabolites and tobacco related alkaloids. These
pretreatment methods include liquid/liquid [13,14], solid-phase
extraction (SPE) [15,16], acid precipitation [17], centrifugation,
and filtration [18]. Although sensitive, these methods are time and
labor intensive. Additionally, the use of SPE columns can be
expensive. A protein/salt precipitation method that uses an
organic solvent, such as acetonitrile or methanol is commonly
applied. The method described here uses acetone precipitation
pretreatment for depleting phospholipids, proteins, and salts from
urine specimens prior to LC-MS/MS analysis. Advantages of the
acetone pretreatment method include lower toxicity (vs. acetoni-
trile), lower cost (vs. SPE), and a lower labor requirement (vs.
liquid/liquid). In this method acetone effectively removes exoge-
nously added enzyme used for the hydrolysis of urinary
glucuronides. Further, acetone evaporates more readily (vs.
methanol, acetonitrile or water)—thus, facilitating sample con-
centration. In this method, we preferentially evaporate acetone
from an acetone/urine mixture leaving residual urine for LC-MS/
MS analysis. By avoiding complete urine evaporation we greatly
enhanced the recovery of the volatile nicotine and nornicotine.
Following the validation of this method, we analyzed urine
specimens collected from 94 cigarette smokers.
Materials and Methods
Chemicals
Chemicals used in this work were obtained from the following
sources: Acetone (Optima, A.C.S., Fisher Scientific, Cat.
#A929SK-4); Acetonitrile (ACS/HPLC Certified Solvent, Hon-
eywell B&J, Cat #AH015-4PC); Ammonium acetate (Fluka
Analytical Cat. #73594-100G-F); Ammonium hydroxide (Certi-
fied A. C. S. PLUS, Fisher Scientific, Cat. #A669S-500);
Hydrochloric acid (HCl) (Certified A.C.S. PLUS, Fisher Scientific,
Cat. #A144-500); Methanol (HPLC/GC, Honeywell B&J, Cat.
#230-4); Water (HPLC Tedia Company, Inc., Cat. #WS2211-
001); b-Glucuronidase (type H-1, from Helix pomatia, Sigma, Cat.
#G0751-2MU).
Working solutions
Enzyme solution. An enzyme solution containing
10,000 units/mL of b-Glucuronidase (type H-1) was prepared
by diluting the purified powder in 0.5 M ammonium acetate
solution with pH of 5.1, adjusted using glacial acetic acid. If stored
at 4–6uC, the enzyme retained sufficient activity for use in this
procedure for up to 2 weeks.
Methanolic HCl solution. 1% concentrated HCl in meth-
anol (1 mL concentrated HCl in 100 mL volumetric flask, q.s.
methanol).
Acidified HPLC water (pH,3). 8 drops of concentrated
HCl added to 4 liters of HPLC water.
Standard materials. Most standard materials were obtained
from Toronto Research Chemicals, Ontario, Canada, including
the following: Cotinine N-oxide (Catalog No. C725200); Cotinine
N-oxide-methyl d3 (Catalog No. C725203); trans-39-Hydroxyco-
tinine (Catalog No. H92450); trans-39-hydroxycotinine-methyl d3
(Catalog No. N427492); (R,S)-Norcotinine (Catalog No. N66200);
(R,S)-Norcotinine-pyridyl d4 (Catalog No. N662002); (R,S)-Nor-
nicotine (Catalog No. N757000); (R,S)-Nornicotine-pyridyl d4
(Catalog No. N757010); Nicotine-Methyl d3 (Catalog
No N412425); (19S, 29S) Nicotine-19-N-oxide (Catalog
No N427500); (+/2)-trans- nicotinine-19-N-oxide-methyl d3 (Cat-
alog No. N427492); (R,S)-Anabasine (Catalog No. A637175);
(R,S)-Anabasine-2,4,5,6-d4 (Catalog No. A637180); (R,S)-Anata-
bine (Catalog No. A637500); and (R,S)-Anatabine-2,4,5,6-d4
(Catalog No. A637505). Additional standards were obtained from
Sigma-Aldrich, St. Louis, MO: (2)-Cotinine, (Catalog No. C-
5923); (2)-Nicotine (Catalog No. N-3876) and from Cambridge
Isotopes Laboratories, Andover, MA: Cotinine-Methyl d3 (Cata-
log No. DLM-1819).
Standard solutions. Standards were prepared and diluted
using high pressure liquid chromatography (HPLC) grade water at
pH ,3. The acidic diluent retards the evaporative loss of nicotine
and nornicotine from solution by keeping these analytes primarily
in the ionized form. Twelve standards were prepared across the
indicated concentration ranges. Table 1 lists lists the reportable
concentration range of the standard solutions (based on 200 mL
sample). To avoid mass spectrometer detector saturation, each of
the 12 standard solutions was diluted by a factor of 5 using acidic
water and the channel electron multiplier (CEM) gain was set to
provide a peak height response below 2.06106 when injecting the
most concentrated standard solution. Following preparation the
standards were dispensed into cryovials and stored at 270uC and
a set was thawed before analysis. Data S1. Standards
preparation scheme.
Internal standard (ISTD) spiking solution. Stock ISTD
solutions (100 mL) for each of the nine deuterated internal
standards were gravimetrically prepared in volumetric flasks using
acidified HPLC water as solvent. Dilute ISTD solutions (20 mg/
mL) were prepared from each of the stock internal standards
solutions, except anatabine-pyridyl-d4 and anabasine-pyridyl-d4,
both prepared at 10 ug/mL. To prepare the ISTD spiking
solution, 100 mL of each of the 9 dilute ISTD solutions was mixed
in a 1 liter volumetric flask and diluted to a final volume of 1 liter
with acidified HPLC water. The ISTD spiking solution was used
for the preparation of each standard level (1–12). Following
Figure 1. Nicotine metabolism. Following nicotine uptake in the
body, nicotine is metabolized to six primary metabolites (cotinine,
hydroxycotinine, norcotinine, nornicotine, cotinine oxide, and nicotine
oxide). Nicotine, cotinine, and trans-39-hydroxycotinine are subsequent-
ly glucuronidated at significant rates.
doi:10.1371/journal.pone.0101816.g001
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preparation of the 12 standard levels, the remaining ISTD spiking
solution was dispensed into 2 mL cryovials and frozen at 220uC.
A new cryovial containing ISTD spiking solution was thawed for
each analytical run (,24 samples). For sample preparation, 50 mL
of ISTD spiking solution was added to each sample vial. The
50 mL ISTD spike contained 100 ng of each analyte, except for
anatabine and anabasine—both 50 ng. Following preparation the
internal standard spiking solution was dispensed into cryovials,
stored at 270uC, and thawed before sample preparation.
Standard calibration. All 12 standard concentrations were
analyzed and processed with each group of samples. Calibration
was based on weighted regression analysis (1/X linear regression)
by use of AB Sciex Analyst software (version 1.4.2). In all cases, an
acceptable regression result required a Y-intercept less than
0.1 ng/mL and a correlation coefficient (r) that was greater than
0.98. Typically r values were .0.99.
Instrumentation
LC-MS/MS analysis was performed using an AB Sciex
(Framingham, MA) API 4000 triple quadrupole mass spectrometer
with an electron ion spray interface and a Peak Scientific
Ltd.(Scotland, UK), model NM20ZA, gas generator. The HPLC
system consisted of a Shimadzu (Kyoto, Japan) SCL-10A system
controller, two Shimadzu SC-10AD pumps, one Shimadzu DGU-
14A degasser and an Agilent (Santa Clara, CA) 1200 series
autosampler and column heater. A Beckman Coulter (Indianap-
olis, IN) model Allegra X-12R refrigerated centrifuge, a Thermo
Fisher (Waltham, MA) Savant SpeedVac System SPD2010, and a
Thermo Fisher Precision oscillating water bath were used during
the sample preparation.
Mass spectrometer (MS). The method employs an isotopic
dilution reverse-phase LC-MS/MS method that uses electrospray
ionization (ESI) and multiple reaction monitoring in positive ion
mode at unit mass resolution to determine simultaneously the
presence of nicotine, six nicotine metabolites and two tobacco
components (anabasine and anatabine) in smokers’ urine.
MS compound-dependent parameter settings—declustering
potential (DP), entrance potential (EP), collision energy (CE),
and collision cell exit potential (CXP)—were optimized using flow
infusion. A syringe pump was used to introduce a solution
containing a single native (not isotopically labeled) or labeled
analyte. The optimal voltage settings were determined for each
analyte and these optimal settings were used for the MS analysis,
except for the cotinine and hydroxycotinine settings. Data S2.
Mass transitions. The concentrations of these latter analytes in
smokers’ urine may greatly exceed the linear limits of the mass
spectrometer if the optimized voltage settings are used. Therefore,
the voltage settings (‘‘CE’’ and ‘‘CXP’’) for cotinine and
hydroxycotinine were de-tuned to yield a lower response by the
detector. De-tuning the optimal voltage settings for these two
analytes allows quantification of both major and minor analytes in
a single injection. Data S3. De-tuning MS compound-
specific parameters.
Because CEM detector saturation is typically reached at a peak
height of 2.06106, the CEM voltage setting was adjusted by
injecting the response reference (hereafter ‘‘method blank’’). The
method blank is a sample in which water replaces both urine and
enzyme and there is no acetone precipitation step. When injecting
the method blank the CEM voltage setting was adjusted to
produce a cotinine ISTD peak height of approximately 1.06105.
This voltage setting provides a method linear response to
approximately 20 times the ISTD (i.e., 1.0 e5 * 20 = 2.0 e6).
Because the most concentrated cotinine standard is 20 times the
cotinine ISTD concentration, a linear response is attained
throughout the standard curve.
HPLC. Base-line chromatographic separation was obtained
with a Phenomenex Gemini-NX, C18, 110A, HPLC column
(4.6 mm6150 mm), 5 mm particle size (Part # 00F-4454-E0) and
Gemini-NX pre-column (Part # AJO-8368). Two in-line filters
were inserted prior to the analytical pre-column. The first filter
uses an A-100X SS frit; the second filter uses an A-103X frit
(Upchurch Scientific). The column oven was maintained at 40uC.
Injection volume was 10 mL. Flow rate was 1.0 mL/min.
Mobile phase ‘‘A’’ was 6.5 mM ammonium acetate in HPLC
grade water with pH adjusted to 10.5 using ammonium hydroxide;
mobile phase ‘‘B’’ was 100% acetonitrile. A Shimadzu SCL-
10AVP controller and two LC-10ADVP binary pumps were
programed to deliver a timed gradient over 13.5 minutes, as
outlined in Table 2.
Sample preparation
We report urine nicotine metabolites as ‘‘free’’ and ‘‘total’’. For
‘‘total’’ sample preparation, we mixed 50 mL (100 ng) of isotopi-
cally labeled ISTD spiking solution, 100 mL of sample urine,
100 mL of HPLC water and 160 ml (1600 units) of enzyme
solution. We then incubated the mixture at 37uC overnight (ca.
21 hours) [19]. If we were determining only ‘‘free’’ forms, we
spiked 200 mL of urine (no water added) with 50 mL of ISTD
solution, replaced the b-glucuronidase solution with an equivalent
volume of water, and omitted the 37uC overnight water bath
Table 1. Standard Concentrations and Reportable Ranges (sample volume 200 mL urine–1:5 dilution factor).
Analyte Internal Standard, ng Standards Range, ng/mL Reportable range*, ng/mL
Cotinine Oxide 100 1 to 2000 5 to 10,000
Nicotine 19 Oxide 100 1 to 4000 5 to 20,000
Hydroxycotinine 100 2 to 8000 10 to 40,000
Norcotinine 100 0.4 to 2000 2 to 10,000
Cotinine 100 2 to 4000 10 to 20,000
Nornicotine 100 0.4 to 2000 2 to 10,000
Anatabine 50 0.4 to 200 2 to 1000
Anabasine 50 0.4 to 200 2 to 1000
Nicotine 100 2 to 4000 10 to 20,000
* Based on 200 mL sample (1 to 5 dilution factor).
doi:10.1371/journal.pone.0101816.t001
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incubation. Then, we added 0.85 mL of cold acetone to each
sample (‘‘free’’ or ‘‘total’’) to initiate the precipitation of salts,
protein, and exogenous enzyme. After mixing, we refrigerated the
samples at 4uC for greater than ten minutes; the resulting
precipitate was removed by centrifugation (30 minutes at ,3200
x g and 4uC). Immediately following centrifugation, we transferred
a portion (,380 mL) of the top urine/acetone solution to a LC
injector vial (with 400 mL limited volume insert) containing 20 mL
of methanolic HCl. Next, the acetone was removed by partial
drying of urine/acetone solution in a Thermo Savant evaporator
for 30 minutes. We directly injected the residual urine supernatant
on the LC–MS/MS.
Quality-control (QC) materials
QC pools were prepared by combining human urine from
smokers and non-smokers in varying proportions to obtain high,
medium or low analyte concentrations. The pools that resulted
from the mixing process were spiked with additional minor
analytes to achieve the desired analyte concentrations. Ten pools
were prepared in support of this study. Final concentrations and
initial quality control limits were determined using a minimum of
twenty runs spread over about six weeks. The total cotinine
concentrations of these pools ranged from 5 to 6000 ng/mL.
Water blanks
A water blank (200 mL of HPLC water as sample) was included
in each analytical run. Water blank calculated concentrations for
each of the nine analytes, other than nornicotine and nicotine,
were mostly not detectable. The upper limit assigned for rejecting
runs on the basis of a high water blank concentration was set at
0.05 ng/mL for all analytes, except for nornicotine and nicotine.
The nornicotine blank upper limit was assigned 0.1 ng/mL and
the nicotine blank upper limit was assigned 0.2 ng/mL. These
latter two analytes tend to be ubiquitous in the environment and
attempting to achieve lower urine blanks was not feasible.
However, for smoker urine assays, the blank levels maintained in
this work are acceptable because the allowable blank upper limits
were well below the lowest reported values for both nornicotine
(2 ng/mL) and nicotine (10 ng/mL). All final results are blank-
corrected by subtraction of the run blank analyte concentrations
from the individual sample analyte concentrations.
Representative chromatograms
Figure 2(A) provides a chromatogram from the analysis of a
mid-range standard with a cotinine value of 200 ng/mL.
Figure 2(B), and Figure 2(C) provide two representative ‘‘free’’
analyses of a smoker’s urine sample. The latter samples had a
measured cotinine concentration of 14.1 ng/mL and 2.77 mg/mL.
Figure 2(D) provides a chromatogram of an enzyme-treated
sample representing a ‘‘total’’ metabolite analysis. The chromato-
grams reflect the typical peak resolution and baseline achieved by
this method.
Method accuracy and precision
A complete set of standards was analyzed and processed with
each group of samples, and these standards were used to calculate
the concentrations of each analyte, as described previously. The
accuracy and precision of this method was examined by analyzing
a series of spiked non-smokers’ urine samples for each of the nine
analytes. Five spiked urine pools (designated, TSV1 thru TSV5)
were prepared by spiking non-smokers’ urine with concentrated
solutions of each analyte and analyzed 20 times over a period of
six weeks. The accuracy and precision observed for this series is
summarized in Table 3. For concentrations found in smoker’s
urine, results differed from the spiked pool target values by no
more than 10% with less than 10% coefficient of variation (CV).
Data S4. Accuracy table 3.
Sample analyte stability
A urine pool was thawed and re-frozen eight times over two
days and analyzed in comparison with samples maintained frozen
at 270uC. No change was observed in the concentration of any of
the nine analytes, or the conjugates. A separate study demon-
strated that nicotine as well as the urine metabolites and
conjugates are stable in urine at room temperature for at least 2
months when stored in sealed cryovials and protected from light.
Storage at room temperature, with light exposure, resulted in some
degradation of nornicotine and nicotine. Data S5. RT light
stability. A degradation of 10–20% was evident for both
nornicotine and nicotine when stored at room temperature in
cryovials and exposed to indirect daylight over a seven week
period. All analytes were stable during the seven week study when
stored in the dark at 4uC or 220uC. Routinely, our urine control
pools and study samples are maintained in low-temperature
freezers at or below –20uC. These studies, and the continued
results from our ongoing analysis of QC pools, demonstrate that
Table 2. HPLC Gradient Elution Table.
Time, min. Module Event Parameter
0.01 Controller Solenoid Valve BBB
0.02 Pumps %B 3
1.00 Pumps %B 3
9.00 Pumps %B 30
10.50 Pumps %B 30
10.51 Pumps %B 100
11.20 Pumps %B 100
11.21 Pumps %B 3
13.50 Controller Stop
*Mobile phase A is 6.5 mM ammonium acetate, pH 10.5.
*Mobile phase B is 100% acetonitrile.
doi:10.1371/journal.pone.0101816.t002
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the metabolites and alkaloids are stable during the analysis and
storage conditions described in this text.
Limit of detection (LOD)
The method detection limits for the analytes were defined as
three times S0, where S0 is the estimate of the standard deviation at
zero analyte concentration. The value of S0 is taken as the y-
intercept of a linear regression of standard deviation versus the
concentration (a minimum of four concentration levels of the
analytes) as specified by Taylor [20] (Table 4). The LOD results
were determined using twenty repetitive analyses of four native-
spiked blank urine pools. For determination of ‘‘total’’ concentra-
tions of each analyte, enzyme digestion was used in the
pretreatment of the urine sample. For ‘‘free’’ analyte concentra-
tions, no enzyme pretreatment was used. Data S6. Precision
and LOD determinations (free + total). The LOD
concentrations reported in Table 4 are much lower that the
lowest reportable analyte concentrations found in Table 1. This is
because the Table 1 concentrations are determined by the lowest
concentration for each analyte in the standards set. In this method,
reportable concentraion limits for each of the analytes in smokers’
urine is the concentration of lowest standard for that analyte in the
standard set, rather that the LOD of the analyte.
Optimization of acetone volume
To estimate the volume of acetone that provides optimal
recovery of the internal spiking solution with low ion suppression,
the acetone volumes used in the precipitation step were varied. A
Figure 2. Representative chromatograms. (A) Standards Analysis (cotinine, 200 ng/mL); (B) Smoker Urine Sample (‘‘free’’ cotinine, 14.1 ng/mL);
(C) Smoker Urine Sample (‘‘free’’ cotinine, 2767 ng/mL); (D) Smoker Urine Sample (‘‘total’’ cotinine, 4195 ng/mL). Abbreviations: Cotinine-oxide (COX);
Nicotine-oxide NOX); Hydroxycotine (HCT); Norcotinine (NCT); Cotinine (COT); Nornicotine (NNC); Anatabine (ANT); Anabasine (ANB); Nicotine (NIC).
The fourth letter ‘‘T’’ in the abbreviations in Figure 2(D) represents the ‘‘total’’ concentrations for measured analytes.
doi:10.1371/journal.pone.0101816.g002
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control pool was analyzed using the procedure described here,
except the volume of acetone used in the precipitation step was
progressively increased from 0.5 mL to 5 mL. As previously
reported for plasma, a ratio of urine to organic solvent of 1: 2 or 1:
2.5 is effective [21,22]. The method described here uses a ratio of
non-organic to organic of ,1: 2.1. Data S7. Acetone volume
for precipitation 1. Data S8. Acetone volume for
precipitation 2.
Optimization of internal standard concentrations
Because the paired native analytes and their labeled internal
standards co-elute, they may compete for ionization in the MS
source. If a very high native nicotine level in a sample suppresses
the detector response of a much lower ISTD, an error in
calculated concentration may occur. In order to maintain a
constant response over the desired quantitation range, one must
properly choose the amount of internal standard used for
standards and for spiking samples [23]. In our method, the
amount of labeled internal standard (100 ng) spiked into 200 mL of
urine is about 20 to 50 times higher than the typical spike used for
determining tobacco exposure in non-smokers. The use of a high
concentration for the labeled ISTD improves the linear range of
the highest standards and samples.
Use of water-based standards versus urine-based
standards
The use of water-based standards has several advantages over
the use of urine-based standards. An important consideration is
the consistency of urine between current and future standard
preparations. Additional considerations include bacterial growth
and decomposition.
To verify that water-based standards and urine based standards
provide similar results when analyzing study samples, we
generated a second standard curve by individually combining
each of the 12 water-based standards (160 mL) with non-smoker
urine (200 mL) to create a urine-based standard set which we then
processed by use of the acetone precipitation procedure. We used
a standard curve generated by these processed urine-based
standards to quantify 18 urine pools (analyte enriched) in
comparison to concentrations generated by use of water-based
standards. Additionally, we generated a third standard curve to
assure that treatment with the enzyme had minimal influence on
the calculated analyte concentrations. To create an enzyme
treated standard curve, the 12 water-based standards (200 mL)
were each combined with enzyme solution (160 mL) and then
processed by use of the acetone precipitation procedure. The
results, as reported in Table 5, indicate that neither the urine nor
the enzyme treatment contributed any discernable bias to the
calculated concentrations of the 18 urine pools. Data S9.
Comparison of water, urine, and enzyme processed
standards Table 5.
Sample recovery
The acetone precipitation step has an internal standard spike
recovery of 76% to 99%. This was determined by preparing a set
of six urine pools in two different ways. First, a set of six samples
was prepared by adding the spiking internal standard in the first
step of the analysis, as usual. In a second set of the same six
samples, the spiking ISTD was added at the end—just before
injection on the LC-MS/MS. When the two sets were injected into
the LC-MS/MS, a comparison of the internal standards area
counts indicated that a loss did not significantly occur during the
precipitation step. However, sample recovery is adversely affected
by both sample loss during acetone precipitation and by loss as a
result of ion suppression during LC-MS/MS analysis. Therefore,
we further examined the effect of matrix ion suppression.
Ion suppression evaluation
To evaluate ion suppression in this method, two urine samples
were analyzed at four levels of increasing dilution. If ion
suppression is influencing the calculated analyte concentrations,
these concentrations would be expected to increase or decrease
with increasing dilution. The results observed are summarized in
Table 6 and demonstrate the good reproducibility of this method
and the low influence of ion suppression on the calculated results.
No substantial change in the analyte concentrations is indicated
following increased dilutions (dilution 5 to dilution 50). All samples
are single injections in a single run. Data S10. Dilution
influence on ion suppression Table 6.
Ruggedness Test
Ruggedness testing was performed to access the influence of
altering several pretreatment variables on the calculated analyte
concentrations. The variables altered include pH of enzyme buffer
solution, enzyme hydrolysis time, and the concentration of
enzyme. The range of variations evaluated had no substantial
effect on the calculated concentrations of the analytes. The results
are displayed in the supplemental data files. Data S11.
Ruggedness testing.
Table 4. Limits of Detection (LOD) for ‘‘free’’ and ’’total’’ analytes.
Analyte ‘‘Free’’, LOD, ng/mL ‘‘Total’’, LOD, ng/mL
Cotinine Oxide 1.77 1.5
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Ethics statement
This study was reviewed and IRB approved by the Institutional
Review Board at the Centers for Disease Control (protocol #6358)
and complied with all national and international guidelines on
research involving human subjects. All study participants provided
written/witnessed consent using a preapproved consent form prior
to donation of specimens. The urine samples tested were from 94
smokers who reported routinely smoking an average of 19
cigarettes/day.
Results and Discussion
Nicotine metabolite profile results
We present here a few initial observations relating to the
distribution of the nicotine metabolites in a subset of samples to
which we applied the method.
Table 7 reports the molar percent of urinary nicotine
metabolites found using this method to the molar percent
compiled from previously reported 24-hour urine studies using
various other methods [24]. The ratios are similar. Because the
half-life of nicotine in serum is about 2 hours, an increase in
nicotine percent in our daytime, spot-collected samples would be
expected. A daytime collection during active smoking would yield
a higher nicotine level than a sample collected following several
hours of sleep, as would occur in a 24 hour urine studies. Data
S12. Molar % of urine metabolites in smokers Table 7.
Anatabine and anabasine as a tobacco exposure
indicators
We evaluated the reliability of urinary anatabine and anabasine
measurements as indicators of active smoking behavior. Anatabine
and anabasine, two tobacco alkaloids that are not metabolites of
nicotine, are included in this method because they have been
measured in smoking cessation programs to validate non-smoking
compliance [11]. Their presence in the urine of program
participants is an indication of tobacco exposure. Recent tobacco
use is indicated by urine concentrations of either alkaloid above
the level of 2 ng/mL [11]. In the group of 94 smokers’ urine
samples, ‘‘total’’ anabasine and ‘‘total’’ anatabine were evaluated
for their usefulness in validating smoking status. Of the 94 smoker
urine samples, 94% had anatabine levels greater than 2 ng/mL.
Only 74% of smokers had anabasine levels above 2 ng/mL. In
addition, 94% had either anatabine or anabasine levels greater
than 2 ng/mL. The mean anatabine level of all smokers was
15.2 ng/mL (range, 1.2 to 62.3 ng/mL). For anabasine the mean
was 6.12 ng/mL (range, ,LOD (0.60) to 30.0 ng/mL). For our
group of heavy smokers, these results indicate that a cut-off of
2 ng/mL for anatabine is a more reliable indicator of smoking
status than anabasine alone and is as reliable an indicator as
combining the smoking status results of both anabasine and
anatabine. These cut-off points may be further improved by
including a measure of variable hydration such as creatinine
correction. Data 13. Anatabine and anabasine levels in 94
smokers.
Acetone as a precipitating agent
As a precipitating agent, acetone and acetonitrile are more
effective in removing protein than is methanol [25]. Although the
effectiveness of removing protein and salt by acetonitrile or
acetone is similar [25], acetone may be more effective in removing
phospholipids because most human endogenous phospholipids are
insoluble in acetone, and acetone is sometimes used in harvesting
phospholipids for quantification in body fluids [26–29]. Removal
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The removal reduces LC maintenance (plugged tubing and frits),
extends column life, and eliminates some potential chromato-
graphic interferences and ion suppressing components.
Matrix ion suppression optimization
Matrix ion suppression should be considered as a possible
source of inaccuracy when one is validating a LC-MS/MS
method. Ion suppression occurs as a result of the presence of
substances in the sample matrix that interfere with ion transmis-
sion by inhibiting analyte ionization and subsequent passage of
ions through the MS orifice. During the development of a LC-
MS/MS method, ion suppression may be addressed by application
of practices that reduce suppression. For simplicity, the practices
considered for limiting suppression in developing this method are
briefly discussed under three headings: sample (preparation,
dilution factor, ISTD); HPLC (mobile phase, injection volume,
gradient elution, and column rinsing); and MS (ionization mode).
Then, we follow with a description of the technique we used to
monitor individual sample injections for excessive ion suppression.
Ion suppression—sample
Sample preparation. Ion suppression may occur in any LC-
MS/MS analysis following diverse types of sample preparation.
Although ion suppression following direct injection or a ‘‘dilute
and shoot’’ (solvent dilution and direct LC-MS/MS injection) or a
‘‘crash and burn’’ (protein precipitation and fast gradient LC-MS/
MS run) method is more frequently present [30], it may also be
observed during sample preparation by SPE or liquid/liquid
extraction [31]. The concentration steps used in SPE or liquid/
liquid sample preparations are a valuable means of increasing
sensitivity and lowering the LOD, but they may also magnify
matrix ion suppression by concentrating the suppressing compo-
nents [32]. In our method, depletion of phospholipids, proteins,
and salts by acetone precipitation eliminates many potential ion
suppressing agents without use of a strong concentrating step,
which is a suitable approach for smokers’ urine samples.
Sample dilution factor. Ion suppression is generally de-
creased by increasing the dilution (addition of water, mobile phase,
solvent) [33]. However, when deciding on an appropriate dilution,
one must consider that excessive dilution can result in reduced
sensitivity, as well as a higher LOD and coefficient of variation. In
this assay, the water addition during the acetone precipitation step
reduced suppression while maintaining suitable sensitivity for the
application.
Sample ISTD. Although the influence of sample matrix on
the calculated concentration of an analyte is greatly diminished by
the use of isotopically labeled internal standards, ion suppression
can either increase or decrease calculated values as well [34,35]. In
this method, isotopically labeled internal standards were used for
all analytes. Because the native analyte and the labeled internal
standard co-elute, they can suppress the response of each other. In
order to maintain a constant response over the desired quantifi-
cation range, one must properly choose the amount of internal
standard used for spiking the sample [23]. In our method, the
amount of labeled internal standard (100 ng) spiked into 200 mL of
urine is about 20 to 50 times higher than the optimal spike
concentration used for determining tobacco exposure in non-
smokers. The use of a higher ISTD is beneficial because it provides
more linearity at the high end of the standard curve and thus
increases the range of reportable results.
Ion suppression—HPLC
HPLC mobile phase. Although the use of an alkaline mobile
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generation and improves sensitivity, the use of alkaline mobile
phase in positive ion mode ionization may also provide
improvement in sensitivity. The use of alkaline mobile phase
may reduce chemical noise, thereby improving the signal-to-noise
ratio—thus resulting in a lower LOD [36,37]. Modifying the pH
of the mobile phase has little effect on the elution time of
phospholipids [38]; however, changing the mobile phase pH may
alter the polarity of some analytes, thus altering elution times on a
reverse phase HPLC column [39]. In the method described here,
the use of alkaline mobile phase improves the resolution of some
analytes (nicotine, nornicotine) since they elute later in the
chromatogram because of polarity shifts. There is no significant
loss in analyte response, and reduced sign-to-noise ratio improves
LOD and facilitates automated integration of analyte peaks.
HPLC injection volume. Injection volumes should be low,
thus maintaining chromatographic resolution and reducing the
amount of suppressing agents competing with the analyte for
ionization in the instrument source [40,41]. Our method uses a
10 mL injection volume.
HPLC gradient. Analytes should be retained and well
resolved by the LC column selected for the liquid chromato-
graphic separation. Analytes eluting early (near the column void)
are commonly affected by ion suppression [42] [43]. However, ion
suppression may be observed at any elution time in a chromato-
graphic separation that uses LC-MS/MS. The ‘‘crash and burn’’
methods in which the sample is precipitated with an organic
solvent and then injected with little or no chromatographic
resolution of the constituents are more susceptible to calculation
inaccuracies because of ion suppression. In our method, no
analytes elute near the column void and all are chromatograph-
ically base-line resolved.
HPLC column rinsing. Rinsing the LC column with a high
concentration of the eluting mobile phase will help avoid carrying
any residual suppressing components into the next injection cycle.
In this urine method, at a flow rate of 1.0 mL/minute, a 0.5
minute column rinse using 100% acetonitrile followed by a 2.3
minute column regeneration to the initial gradient conditions was
completed following each sample run. Our method analyzes urine
samples; however, for some biological matrixes (blood, tissue
extracts), an extended rinsing cycle with 100% eluting organic
phase may be required.
MS ionization mode
Two modes of ionization are available on the Sciex API 4000,
ESI or atmospheric pressure chemical ionization (APCI). Although
APCI is usually less susceptible to ion suppression than ESI
[42,44,45], the use of APCI is not always applicable. ESI is used in
our method because one of the analytes (nicotine 19-N-oxide) is
heat labile, and quantification by APCI is not possible.
Ion suppression monitoring
Because ion suppression may occur at any point in a
chromatographic elution and may vary among samples, it is
desirable to have a dynamic evaluation of the ion suppression for
each MS transition with each sample injection. In our method, to
assess ion suppression in each sample, we compared the area of the
internal standard recovered following LC-MS/MS injection of a
urine sample to the internal standard recovered following the
method blank injection [46]. As previously discussed, the method
blank is a sample in which the urine is replaced by water and the
acetone precipitation step is deleted. In our method, the ‘‘method
blank’’ contains: 50 mL internal standard spiking solution, 360 mL
water (replaces urine and enzyme), and 20 mL methanolic HCl.
Because matrix urine components are absent, ion suppression is
very low in the ‘‘method blank’’. This comparison (sample ISTD
to blank ISTD counts) does not provide an exact representation of
the ion-suppression, but it does allow for detection of excessive
suppression that may adversely affect calculated concentrations.
Hoofnagle [47] determined that an imprecision of 25% was not
reached unless the internal standard count was suppressed more
than 90%. For our method, an ion suppression of greater than
50% flags the analysis to be repeated at a higher dilution. Diluting
the sample reduces the ion suppression–a concept used in ‘‘dilute
and shoot’’ methods.
Monitoring a second transition for the native analyte being
quantified and establishing a nominal ratio between the areas of
the two transitions may aid in detecting the presence of any
interfering compound or of severe ion suppression. In our method,
we monitor two transitions for each analyte and we monitor the
calculated ratio (confirm/quant ratio) to flag samples requiring
repeat analysis.
Summary of method validation
Our validation of this method for nicotine, six nicotine
metabolites, anatabine and anabasine has demonstrated its
accuracy over the wide concentration range of smokers’ urine
specimens. Prior to the development of this method, multiple
dilutions of smokers’ urine samples were required because of the
limited linear range of the API 4000 mass spectrometer. As
described, the range of reportable analyte concentrations was
extended by diluting the standards to achieve linear responses at
the highest standard levels (ranges, Table 1), by the use of
appropriate concentrations of isotopically labeled internal stan-
dards for each analyte, and by de-tuning the API 4000 instrument
parameters (‘‘CE’’ and ‘‘CXP’’) for the two most abundant
metabolites, cotinine and hydroxycotinine.
We verified the accuracy and precision of the method by use of
spiked non-smoker urine pools (Table 3) and demonstrated the
stability of the analytes during storage and analysis. The acetone
precipitation pretreatment provides high mean metabolite recov-
ery (76–99%) and analysis of the residual urine supernatant by the
API 4000 produced LODs ranging from 0.41 to 3.53 ng/mL
(Table 4). We employed progressive dilution of two smoker’s
urine samples to evaluate inaccuracies introduced by excessive ion
suppression (Table 5). We confirmed that the use of water-based
and urine-based standards both provide similar regression curves
and provide calculated concentration differences of less than +/2
3% when used to analyze 18 random smokers’ urine samples
(Table 6). We obtained chromatographically base-line resolution
of all analytes (Figure 2, A-D) to reduce the possibility of
interferences and ion suppression in random non-conforming
samples.
Conclusion
Acetone precipitation prior to LC-MS/MS analysis of urine
components is a simple, accurate, inexpensive, relatively non-toxic
sample preparation method. Although acetone precipitation is not
commonly employed in the LC-MS/MS analysis of non-precip-
itated residual small molecules in a urine matrix, the removal of
phospholipids, protein, and salts by acetone precipitation is
effective in producing a sample that is highly compatible with
analysis by LC-MS/MS. Because of acetone’s high volatility, the
acetone can be evaporated from the urine/acetone supernatant
following precipitation, leaving the residual urine supernatant for
injection. Being able to avoid complete dry-down of the urine
sample improves recovery of the volatile analytes, especially
nicotine and nornicotine. Simplicity, low-cost, low maintenance
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PLOS ONE | www.plosone.org 11 July 2014 | Volume 9 | Issue 7 | e101816
combined with high mean metabolite recovery (76–99%),
specificity, accuracy (0-10% bias) and reproducibility (2-9%
C.V.) make this method ideal for large high through-put studies.
Acetone precipitation will likely be employed frequently in future
analysis of urine small molecular components by LC-MS/MS. We
look forward to exploring other applications.
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